Biosimilars

An unlikely partnership between a rural church and a treatment center is bringing a mobile clinic to Western North Carolina, offering hope on the front lines.

New Medicare billing codes for the biosimilar Tyenne are now in effect, simplifying reimbursement and aiming to improve access for severe COVID-19 patients.

As Option Care Health preps its Q1 results, investors watch if it can seize market share from a retreating rival while navigating major biosimilar headwinds.

At AAN 2026, SK Life Science will present new cenobamate data and survey findings that expose a critical communication gap in epilepsy care.

President Trump's 100% tariff on imported drugs aims to secure the US supply chain, but the policy's success may hinge on unproven and unverified players.

A new tool reveals how a federal drug program may be inflating healthcare costs for businesses, intensifying the debate over transparency and reform.

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

Parnell’s nixiFLOR, the first generic of Resflor Gold®, offers a cost-effective new weapon for ranchers battling Bovine Respiratory Disease.

With its lead drug for a rare pediatric liver disease entering late-stage trials, NorthSea Therapeutics adds a veteran drug developer to its board.

Landmark study results show a new drug-coated balloon significantly improves outcomes for Peripheral Artery Disease, heralding a major shift in treatment.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

The FDA has clarified its rules for desiccated thyroid extract (DTE), providing relief for patients and a new path forward for manufacturers like Acella.

Maze Therapeutics posts positive Phase 2 data for its genetic kidney disease drug, but a sharp stock drop reveals investor concerns in a competitive race.

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.

With a new CFO who helped steer a multi-billion dollar acquisition, Bambusa Therapeutics signals major growth plans for its innovative antibody platform.

BioCardia's FDA milestone for its Helix catheter could unlock a new era of targeted heart therapies, but financial hurdles and clinical questions remain.

An Alabama firm's key regulatory filing for a critical drug component could accelerate the development of cheaper cancer supportive care biosimilars.

Amid fierce competition, Triangle Insights Group hires a seasoned expert to guide clients through the complex world of drug pricing and market access.

Eledon's tegoprubart gets Orphan Drug status, signaling a new era for liver transplant patients by potentially replacing toxic, decades-old therapies.

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.